Categories
Fashion

Global Cancer Monoclonal Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

DUBLIN, Sept. 16, 2021 /PRNewswire/ — Gain comprehensive access to over 550 cancer monoclonal antibody deal records from this report "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2021" that has been added to ResearchAndMarkets.com’s offering.

This report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering deals

Most active companies in cancer monoclonal antibody partnering

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer monoclonal antibody partnering contract documents

Top cancer monoclonal antibody deals by value

This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering: Monoclonal antibodies

Murine mAb

Chimeric mAb

Humanized mAb

Human aAb

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of […]

Leave a Reply

Your email address will not be published. Required fields are marked *